NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
TXG
10x Genomics, Inc.
TXG has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TXG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Strong | |
| Unavailable |
TXG's cash flow is currently strong, and its revenue is stable, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
TXG PE Valuation
TXG has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TXG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
TXG has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over TXG on earnings quality, reporting a profit while its opponent remains loss making.
TXG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.52 | +$0.10 |
| Q2 2026 | -$0.59 | +$0.11 |
| Q1 2026 | -$0.17 | +$1.13 |
| Q4 2025 | -$0.35 | +$1.17 |
| Q3 2025 | -$0.62 | +$0.92 |
| Q2 2025 | -$0.70 | +$1.33 |
| Q1 2025 | -$1.30 | +$0.94 |
| Q4 2024 | -$1.52 | +$0.66 |
TXG is still losing money, but far less than before: $0.52 per share over the past year, against $5.37 at its worst in late 2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over TXG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over TXG on profitability, with a higher operating margin.
TXG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $150.7M | +1.1% |
| Q2 2026 | $151M | -13% |
| Q1 2026 | $150.8M | -2.6% |
| Q4 2025 | $166M | +0.6% |
| Q3 2025 | $149M | -1.7% |
| Q2 2025 | $172.9M | +13% |
| Q1 2025 | $154.9M | +9.8% |
| Q4 2024 | $165M | -10% |
TXG's revenue fell from its 2023 peak and has held roughly level since: $151M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11% | +11 points |
| Q2 2026 | -13% | -30 points |
| Q1 2026 | -11% | +14 points |
| Q4 2025 | -12% | +18 points |
| Q3 2025 | -22% | +5.7 points |
| Q2 2025 | 17% | +45 points |
| Q1 2025 | -25% | +18 points |
| Q4 2024 | -30% | -0.2 points |
TXG's operating margin was −11% last quarter, up 11 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over TXG on cash flow, with more consistent year-over-year improvement.
TXG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.9M | -65% |
| Q2 2026 | $15.4M | -4.6% |
| Q1 2026 | $24.5M | -24% |
| Q4 2025 | $39M | +$48.5M |
| Q3 2025 | $42.5M | +140% |
| Q2 2025 | $16.1M | +249% |
| Q1 2025 | $32.5M | +$51.1M |
| Q4 2024 | -$9.5M | -142% |
TXG has burned cash in most quarters: $94M over the past year, up 15% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over TXG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
TXG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +822K shares |
| 1 year | +4.2% | +5.3M shares |
| 3 years | +11% | +13.1M shares |
| 5 years | +18% | +19.9M shares |
| Available history | +35% | +34M shares |
TXG has 131M diluted shares, up 4.2% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
TXG Net Leverage
TXG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TXG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.2 | Neutral |
| Stochastic | 28.5 | Neutral |
TXG's weekly RSI is 52 (neutral) and its Stochastic is 28 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TXG PE vs Healthcare Sector
TXG has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
TXG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $73.7 | 20% below |
| 20 week MA | $62.6 | 5.5% below |
| 50 week MA | $38.3 | 54% above |
| 100 week MA | $25.3 | 134% above |
| 200 week MA | $31.8 | 86% above |
TXG has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
TXG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.2 | $151.3 | +94% |
| 2021 | $151.3 | $146.1 | -3.5% |
| 2022 | $146.1 | $34.2 | -77% |
| 2023 | $34.2 | $56.0 | +63% |
| 2024 | $56.0 | $14.6 | -74% |
| 2025 | $14.6 | $16.5 | +13% |
| 2026 YTD | $16.5 | $59.1 | +258% |
TXG has the edge over NVO on returns for 2026, with the stronger performance.